Developer docs
API playgroundTry for free, no card

Search company profiles

Zinexts Life Science

Full company profile

uuid000olcc

Namestring
Zinexts Life Science
Legal namestring
Zinexts Life Science
Websiteurl
zinexts.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Zinexts Life Science is a private Taiwanese biotechnology company founded in 2011 and headquartered in Taipei that develops and manufactures molecular diagnostics systems marketed as deployment-ready, FDA-aligned solutions for clinical integration. The company positions its hardware within the broader "Bio ICT" framing of Taiwan's medical-device export sector, emphasizing edge-AI capabilities, supply-chain resilience, and production-grade diagnostics in contrast to what it characterizes as pilot-phase AI applications. Its core product is a molecular diagnostic system sold to healthcare providers and health systems, with explicit targeting of the U.S. clinical market.

The company operates with a small headcount of 11–50 employees and an enterprise-oriented go-to-market built around two reinforcing motions: event-driven demand generation via the Taiwan Excellence national pavilion (most visibly at HIMSS 2026 in Las Vegas, organized by TAITRA), and direct B2B enterprise field sales targeting American health systems. It co-markets alongside complementary Taiwanese vendors — SURGLASSES, Imedtac, and Wincomm — presenting an integrated smart-healthcare stack to North American buyers. No public pricing, named customers, management team, funding history, or revenue figures are disclosed.

Strategically, Zinexts leans on Taiwan's established medical-device export infrastructure, where Taiwan's medical device exports reached US$3.78 billion in 2025 and the United States accounted for 25.7% of that total. The company frames FDA alignment and supply-chain resilience as its primary differentiators, while relying on national trade-promotion programs rather than individually built distribution to access U.S. clinical buyers. The combination of a small operating footprint, undisclosed financials, and externally provided market access suggests an early-stage international expansion rather than a scaled commercial operation.

Short descriptiontext

Zinexts Life Science is a private Taiwanese biotechnology company founded in 2011 that develops molecular diagnostics systems with edge-AI capabilities for healthcare providers and health systems, primarily targeting the U.S. market through enterprise sales and trade-show channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTaipei, Taiwan
HQ citystring
Taipei
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
molecular diagnostics systems, clinical laboratory equipment, molecular biology reagents, IVD medical devices, edge-AI diagnostics
Industry1 code
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics Equipment
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Molecular Diagnostics Hardware Sales
TypeHardware Sales
Description

Sale of molecular diagnostic systems and medical technology hardware to healthcare providers and health systems, with emphasis on deployment-ready solutions for clinical integration.

businesswire.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Zinexts Life Science develops and manufactures molecular diagnostics systems for clinical laboratory and point-of-care applications. The company's core offering is deployment-ready molecular diagnostic instruments with edge-AI capabilities, designed for immediate integration into U.S. health system workflows as production-ready solutions rather than pilot-phase AI applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Part of Taiwan's US$3.78 billion medical device export industry with 25.7% market share in U.S.
Product overview1 text field

Zinexts Life Science offers molecular diagnostics systems as its core product offering. The company participates in the broader Taiwan Excellence ecosystem alongside other Taiwanese healthcare innovators (Imedtac, SURGLASSES, Wincomm) at international trade shows. At HIMSS 2026, Zinexts demonstrated its molecular diagnostic systems alongside smart medication cabinets (Imedtac), AR surgical navigation (SURGLASSES), and medical-grade point-of-care PCs (Wincomm), positioning these as complementary deployment-ready AI healthcare solutions for the U.S. market.

Product and service1 record
1Molecular Diagnostics Systems
CategoryMolecular Diagnostics Equipment
Description

Deployment-ready molecular diagnostic instruments with edge-AI capabilities designed for clinical integration and immediate deployment by healthcare providers and health systems. Built for production use rather than pilot-phase applications, with FDA-aligned compliance.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-03-10
Description

TAITRA organized and hosted the Taiwan Excellence Pavilion at HIMSS 2026, providing the primary platform for Zinexts to showcase deployment-ready molecular diagnostics systems. TAITRA serves as Taiwan's official trade promotion body facilitating international trade relationships.

2TITA (Taiwan International Trade Association)
Strategic tierSupportingTypeGTM or Marketing Partner
Description

TITA supported the Taiwan Excellence Pavilion at HIMSS 2026, contributing to the national initiative showcasing deployment-ready AI healthcare solutions from Taiwanese brands including Zinexts.

businesswire.com
3Taiwan Excellence
Strategic tierCoreTypeGTM or Marketing Partner
Description

Taiwan Excellence is a national brand initiative that organized the pavilion at HIMSS 2026, featuring eleven Taiwanese healthcare technology brands including Zinexts, demonstrating the shift from AI promise to production in healthcare technology.

aijourn.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Fellow Taiwanese healthcare technology company showcased alongside Zinexts at the HIMSS 2026 Taiwan Excellence Pavilion, demonstrating AR surgical navigation and smart healthcare solutions as part of the collaborative national showcase.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Fellow Taiwanese company at HIMSS 2026 Taiwan Excellence Pavilion showcasing smart medication cabinets alongside Zinexts' molecular diagnostics systems as part of the integrated smart healthcare ecosystem demonstration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Taiwanese medical technology company co-showcasing at HIMSS 2026 with medical-grade point-of-care PCs, part of the complementary product ecosystem alongside Zinexts' molecular diagnostics at the Taiwan Excellence Pavilion.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Hologic's Panther system is a high-throughput molecular diagnostics platform widely used in hospital and reference-lab settings. It competes directly with Zinexts in the clinical molecular-diagnostics instrumentation and consumables market.

TypeDirect peer
Description

ELITechGroup manufactures molecular diagnostics instruments and reagents (e.g., InGenius, ELITe InGenius) for hospital and clinical labs. As a focused, mid-sized molecular-diagnostics instrumentation vendor, it is closely comparable to Zinexts in product scope and target customer.

TypeRegional player
Description

Bioneer is a Korean molecular diagnostics and life-science reagents company that develops molecular biology instruments and AccuPower test kits for clinical and research use. It is comparable to Zinexts as a similarly sized Asian-headquartered molecular diagnostics hardware manufacturer targeting international expansion.

TypeBroad incumbent
Description

bioMérieux's BioFire FilmArray is a leading syndromic molecular diagnostics platform installed across U.S. hospitals. It is a direct functional competitor to Zinexts in clinical molecular diagnostics and shares the same hospital-lab buyer.

TypeDirect peer
Description

GenMark, now part of Roche, commercializes the ePlex molecular diagnostics system for hospital labs and is a direct peer in clinical molecular-diagnostics instrumentation targeting similar enterprise health-system customers as Zinexts.

TypeBroad incumbent
Description

Cepheid, owned by Danaher, is the dominant molecular diagnostics platform vendor with its GeneXpert system deployed across U.S. hospitals. It represents the entrenched incumbent that Zinexts must displace or differentiate against in the same clinical molecular-diagnostics category.

7Abbott Molecular
TypeBroad incumbent
Description

Abbott's m2000 and Alinity m systems are widely deployed molecular diagnostics platforms serving hospital labs and reference labs. Comparable to Zinexts as a large, established molecular diagnostics hardware and consumables vendor targeting the same clinical end users.

TypeBroad incumbent
Description

QIAGEN offers a portfolio of molecular diagnostics instruments (e.g., QIAstat-Dx) and sample-preparation technologies serving hospital and clinical lab customers. Comparable to Zinexts in product category and clinical end-user focus.

TypeEmerging player
Description

QuantuMDx is a smaller molecular diagnostics company developing portable, rapid molecular testing systems for clinical and decentralized settings. Comparable to Zinexts as an emerging hardware platform with AI/digital integration targeting hospital and clinical lab buyers.

TypeBroad incumbent
Description

Roche operates the cobas family of molecular diagnostics systems installed in large hospital and reference-lab networks globally. It is the broadest incumbent in clinical molecular diagnostics and the natural competitor to any new molecular-diagnostics platform entering U.S. health systems.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zinexts Life Science

Molecular Diagnostics Equipmentzinexts.com

Zinexts Life Science is a private Taiwanese biotechnology company founded in 2011 that develops molecular diagnostics systems with edge-AI capabilities for healthcare providers and health systems, primarily targeting the U.S. market through enterprise sales and trade-show channels.

What Zinexts Life Science does

Zinexts Life Science is a private Taiwanese biotechnology company founded in 2011 and headquartered in Taipei that develops and manufactures molecular diagnostics systems marketed as deployment-ready, FDA-aligned solutions for clinical integration. The company positions its hardware within the broader "Bio ICT" framing of Taiwan's medical-device export sector, emphasizing edge-AI capabilities, supply-chain resilience, and production-grade diagnostics in contrast to what it characterizes as pilot-phase AI applications. Its core product is a molecular diagnostic system sold to healthcare providers and health systems, with explicit targeting of the U.S. clinical market.

The company operates with a small headcount of 11–50 employees and an enterprise-oriented go-to-market built around two reinforcing motions: event-driven demand generation via the Taiwan Excellence national pavilion (most visibly at HIMSS 2026 in Las Vegas, organized by TAITRA), and direct B2B enterprise field sales targeting American health systems. It co-markets alongside complementary Taiwanese vendors — SURGLASSES, Imedtac, and Wincomm — presenting an integrated smart-healthcare stack to North American buyers. No public pricing, named customers, management team, funding history, or revenue figures are disclosed.

Strategically, Zinexts leans on Taiwan's established medical-device export infrastructure, where Taiwan's medical device exports reached US$3.78 billion in 2025 and the United States accounted for 25.7% of that total. The company frames FDA alignment and supply-chain resilience as its primary differentiators, while relying on national trade-promotion programs rather than individually built distribution to access U.S. clinical buyers. The combination of a small operating footprint, undisclosed financials, and externally provided market access suggests an early-stage international expansion rather than a scaled commercial operation.

Zinexts Life Science firmographics

Firmographics
Name
Zinexts Life Science
Legal name
Zinexts Life Science
Website
https://zinexts.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Zinexts Life Science is a private Taiwanese biotechnology company founded in 2011 that develops molecular diagnostics systems with edge-AI capabilities for healthcare providers and health systems, primarily targeting the U.S. market through enterprise sales and trade-show channels.
Ownership category
akta.pro rank

Zinexts Life Science industry classification

Industry
Product category
Molecular Diagnostics Equipment
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Molecular diagnostics systems
  • Clinical laboratory equipment
  • Molecular biology reagents
  • IVD medical devices
  • Edge-AI diagnostics

Where Zinexts Life Science is headquartered

Location

Headquarters

HQ city
Taipei
HQ country
Taiwan
HQ region
Asia

Markets served

Zinexts Life Science business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Molecular Diagnostics Hardware Sales: Sale of molecular diagnostic systems and medical technology hardware to healthcare providers and health systems, with emphasis on deployment-ready solutions for clinical integration.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Zinexts Life Science product offering

Product offering

Core offering

Zinexts Life Science develops and manufactures molecular diagnostics systems for clinical laboratory and point-of-care applications. The company's core offering is deployment-ready molecular diagnostic instruments with edge-AI capabilities, designed for immediate integration into U.S. health system workflows as production-ready solutions rather than pilot-phase AI applications.

Product overview

Zinexts Life Science offers molecular diagnostics systems as its core product offering. The company participates in the broader Taiwan Excellence ecosystem alongside other Taiwanese healthcare innovators (Imedtac, SURGLASSES, Wincomm) at international trade shows. At HIMSS 2026, Zinexts demonstrated its molecular diagnostic systems alongside smart medication cabinets (Imedtac), AR surgical navigation (SURGLASSES), and medical-grade point-of-care PCs (Wincomm), positioning these as complementary deployment-ready AI healthcare solutions for the U.S. market.

Differentiator

Problem solved

Functional benefit

Products and services

  • Molecular Diagnostics Systems Deployment-ready molecular diagnostic instruments with edge-AI capabilities designed for clinical integration and immediate deployment by healthcare providers and health systems. Built for production use rather than pilot-phase applications, with FDA-aligned compliance.

Quantifiable outcome

  • Part of Taiwan's US$3.78 billion medical device export industry with 25.7% market share in U.S.

Companies that use Zinexts Life Science

Customer profile

Segments2 records

Ideal customer profiles1 record

Zinexts Life Science technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Zinexts Life Science partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, supporting and minor.

  • TAITRA (Taiwan External Trade Development Council)coreGTM or Marketing Partner · 10 March 2026TAITRA organized and hosted the Taiwan Excellence Pavilion at HIMSS 2026, providing the primary platform for Zinexts to showcase deployment-ready molecular diagnostics systems. TAITRA serves as Taiwan's official trade promotion body facilitating international trade relationships.
  • TITA (Taiwan International Trade Association)supportingGTM or Marketing PartnerTITA supported the Taiwan Excellence Pavilion at HIMSS 2026, contributing to the national initiative showcasing deployment-ready AI healthcare solutions from Taiwanese brands including Zinexts.
  • Taiwan ExcellencecoreGTM or Marketing PartnerTaiwan Excellence is a national brand initiative that organized the pavilion at HIMSS 2026, featuring eleven Taiwanese healthcare technology brands including Zinexts, demonstrating the shift from AI promise to production in healthcare technology.
  • SURGLASSESminorStrategic or Co-development PartnerFellow Taiwanese healthcare technology company showcased alongside Zinexts at the HIMSS 2026 Taiwan Excellence Pavilion, demonstrating AR surgical navigation and smart healthcare solutions as part of the collaborative national showcase.
  • ImedtacminorStrategic or Co-development PartnerFellow Taiwanese company at HIMSS 2026 Taiwan Excellence Pavilion showcasing smart medication cabinets alongside Zinexts' molecular diagnostics systems as part of the integrated smart healthcare ecosystem demonstration.
  • WincommminorStrategic or Co-development PartnerTaiwanese medical technology company co-showcasing at HIMSS 2026 with medical-grade point-of-care PCs, part of the complementary product ecosystem alongside Zinexts' molecular diagnostics at the Taiwan Excellence Pavilion.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Zinexts Life Science competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Hologic's Panther system is a high-throughput molecular diagnostics platform widely used in hospital and reference-lab settings. It competes directly with Zinexts in the clinical molecular-diagnostics instrumentation and consumables market.
  • bioMérieux (BioFire): bioMérieux's BioFire FilmArray is a leading syndromic molecular diagnostics platform installed across U.S. hospitals. It is a direct functional competitor to Zinexts in clinical molecular diagnostics and shares the same hospital-lab buyer.
  • Cepheid (Danaher): Cepheid, owned by Danaher, is the dominant molecular diagnostics platform vendor with its GeneXpert system deployed across U.S. hospitals. It represents the entrenched incumbent that Zinexts must displace or differentiate against in the same clinical molecular-diagnostics category.
  • Abbott Molecular: Abbott's m2000 and Alinity m systems are widely deployed molecular diagnostics platforms serving hospital labs and reference labs. Comparable to Zinexts as a large, established molecular diagnostics hardware and consumables vendor targeting the same clinical end users.
  • QIAGEN: QIAGEN offers a portfolio of molecular diagnostics instruments (e.g., QIAstat-Dx) and sample-preparation technologies serving hospital and clinical lab customers. Comparable to Zinexts in product category and clinical end-user focus.
  • Roche Diagnostics: Roche operates the cobas family of molecular diagnostics systems installed in large hospital and reference-lab networks globally. It is the broadest incumbent in clinical molecular diagnostics and the natural competitor to any new molecular-diagnostics platform entering U.S. health systems.

Direct peers

  • ELITechGroup: ELITechGroup manufactures molecular diagnostics instruments and reagents (e.g., InGenius, ELITe InGenius) for hospital and clinical labs. As a focused, mid-sized molecular-diagnostics instrumentation vendor, it is closely comparable to Zinexts in product scope and target customer.
  • GenMark Diagnostics (Roche): GenMark, now part of Roche, commercializes the ePlex molecular diagnostics system for hospital labs and is a direct peer in clinical molecular-diagnostics instrumentation targeting similar enterprise health-system customers as Zinexts.

Regional players

  • Bioneer: Bioneer is a Korean molecular diagnostics and life-science reagents company that develops molecular biology instruments and AccuPower test kits for clinical and research use. It is comparable to Zinexts as a similarly sized Asian-headquartered molecular diagnostics hardware manufacturer targeting international expansion.

Emerging players

  • QuantuMDx: QuantuMDx is a smaller molecular diagnostics company developing portable, rapid molecular testing systems for clinical and decentralized settings. Comparable to Zinexts as an emerging hardware platform with AI/digital integration targeting hospital and clinical lab buyers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Zinexts Life Science social profiles

Digital presence

Zinexts Life Science financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zinexts Life Science leadership team

Management profile

Number of profiles

Zinexts Life Science funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zinexts Life Science M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zinexts Life Science

What does Zinexts Life Science do?

Zinexts Life Science develops and manufactures molecular diagnostics systems for clinical laboratory and point-of-care applications. The company's core offering is deployment-ready molecular diagnostic instruments with edge-AI capabilities, designed for immediate integration into U.S. health system workflows as production-ready solutions rather than pilot-phase AI applications.

Is Zinexts Life Science a public or private company?

Zinexts Life Science is a private company. It is classified as unknown and is currently operating.

When was Zinexts Life Science founded?

Zinexts Life Science was founded in 2011. It employs 11 to 50 people.

Where is Zinexts Life Science based?

Zinexts Life Science is headquartered in Taipei, Taiwan, in the Asia region.

How does Zinexts Life Science make money?

One revenue line is on record: molecular Diagnostics Hardware Sales.

Who are Zinexts Life Science's main competitors?

Broad incumbents on record are Hologic, bioMérieux (BioFire), Cepheid (Danaher), Abbott Molecular, QIAGEN and Roche Diagnostics. Direct peers are ELITechGroup and GenMark Diagnostics (Roche). Bioneer is listed as a regional player. QuantuMDx is listed as an emerging player.

Does Zinexts Life Science have an API?

No public API is recorded for Zinexts Life Science.

What industry is Zinexts Life Science in?

Zinexts Life Science's product category is Molecular Diagnostics Equipment. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales